-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Review of Efficacy and Safety of Monjuvi (tafasitamab-cxix) : FDA-Approved Monoclonal Antibody in Combination with Lenalidomide for Adult Patients with R/R DLBCL Who Have Received at Least One Prior Therapy

Program: Product Theaters
Session: Review of Efficacy and Safety of Monjuvi (tafasitamab-cxix) : FDA-Approved Monoclonal Antibody in Combination with Lenalidomide for Adult Patients with R/R DLBCL Who Have Received at Least One Prior Therapy
Sunday, December 6, 2020, 11:00 AM-12:00 PM

Susan Snodgrass, MD

Incyte Corporation, Wilmington, DE

Disclosures: No relevant conflicts of interest to declare.

See more of: Review of Efficacy and Safety of Monjuvi (tafasitamab-cxix) : FDA-Approved Monoclonal Antibody in Combination with Lenalidomide for Adult Patients with R/R DLBCL Who Have Received at Least One Prior Therapy
See more of: Product Theaters